BDTX-1535 is under clinical development by Black Diamond Therapeutics and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Recurrent Glioblastoma Multiforme (GBM) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BDTX-1535’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BDTX-1535 overview
BDTX-1535 is under development for the treatment of recurrent glioblastoma, non-small cell lung cancer (NSCLC), high grade glioma and newly diagnosed glioblastoma. The drug candidate is administered orally and acts by targeting the family of epidermal growth factor receptor (EGFR) variants implicated in glioblastoma, as well as Exon 18 mutations and the C797S mutations in NSCLC. It is being developed based on MAP (mutation, allostery and pharmacology) platform.
Black Diamond Therapeutics overview
Black Diamond Therapeutics (Black Diamond) is a precision oncology medicine company. It discovers small molecules and tumor agnostic therapies for the treatment of cancer. The company’s pipeline product candidates include BDTX- 4933 is designed to be a brain penetrant and highly selective and potent inhibitor of oncogenic BRAF Class I, II, III and active RAF dimers promoted by upstream oncogenic alterations; and BDTX-1535, a brain-penetrant small-molecule inhibitor for the treatment of glioblastoma, affecting the brain or spine. It is also developing its Mutation-Allostery-Pharmacology (MAP) technology platform, to identify oncogenic mutations that promote cancer. Black Diamond is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of BDTX-1535’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
